Slide 1: Soligenix
(SOLIGENIX OTC BB: SNGX
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook” and simil
Slide 3: Soligenix
Soligenix Soligenix, Inc. is a development stage, publically-traded, biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, as well as vaccine technology in the areas of biodefense and infectious disease
Slide 4: Value Proposition
Value Proposition + Diversified portfolio: BioTherapeutics and Vaccines/BioDefense + Multiple programs in rare disease and areas of unmet medical need + Significant NIH/FDA grant support for most programs + Experienced management and board of directors Corporate + End of first quarter 2012 cash appr
Slide 5: Pipeline
Pipeline BioTherapeutics Preclinical Phase 1 Phase 2 Phase 3 'SGX201 Radiation Enteritis 'SGX203 Pediatric Crohn's Disease nt forBec® Prevention of Acute GVHD = = forBec® ‘Treatment of Chronic GI GVHD tinnbiditinn IPM™ Leuprolide a Prostate Cancer/Endometriosis Proof of Concept | Animal Phase 1 Phas
Slide 6: Senior Management Team
Senior Management Team + 23 years of experience Discovery Laboratories, Inc. (COO) Christopher J. Schaber, PhD + Acute Therapeutics, Inc. (Co-Founder) President & CEO + Ohmeda PPD, Inc. + The Liposome Company, Inc. + Wyeth Ayerst + 29 years of experience Robert Brey, PhD + Lederle-Praxis, division o
Slide 7: Independent Board Directors
Independent Board Directors + 35 years of experience Keith Brownlie, CPA gEMeTe Young + 20 years of experience + Sigma-Tau Pharmaceuticals, Inc. + AstenJohnson, Inc + Price Waterhouse Coopers Gregg Lapointe, CPA, MBA + 36 years of experience + The Lewin Group Robert Rubin, MD + Georgetown University
Slide 8: BioTherapeutics
BioTherapeutics SOLIGENIX °
Slide 9: Oral Beclomethasone Dipropionate
Oral Beclomethasone Dipropionate * Oral Beclomethasone Dipropionate (BDP) — Potent, topically active, anti- inflammatory steroid - Designed to treat inflammation within lining of Gl tract + Strategy is to decrease need for prolonged use of high dose systemic prednisone - Superior safety profile comp
Slide 10: SGX201 - Acute Radiation Enteritis
SGX201 - Acute Radiation Enteritis + Block inflammatory component of acute radiation enteritis in Gl tract in rectal cancer patients receiving radiation therapy ; * Acute radiation enteritis affects over 100,000 rectal cancer patients world Opportunity wide annually + No approved therapies; area of
Slide 11: SGX203 - Pediatric Crohn's Disease
SGX203 - Pediatric Crohn’s Disease + Inflammation that can affect GI tract from the mouth to the colon + Over 200,000 children/adolescents with Crohn's disease worldwide — 50% have disease proximal to terminal ileum + ~ 80% treated with steroids off-label as first-line therapy; adrenal suppression a
Slide 12: SGX203 - Targeted Approach to GI Inflammation
SGX203 - Targeted Approach to GI Inflammation Two-Pill System + Each tablet contains 1 mg BDP + 1 Immediate Release (IR) tablet designed to release in the upper Gl tract and 1 Delayed Release (DR) tablet designed to release in the lower Gl tract Diagram showing dispersion of IR tablet in the stomach
Slide 13: Vaccine/BioDefense
Vaccine/BioDefense Addressing Critical Concerns for Industry and Government SOLIGENIX
Slide 14: Vaccines/BioDefense Business Model
Vaccines/BioDefense Business Model Soligenix
Slide 15: ThermoVax Vaccine Thermostability Platform
ThermoVax™ Vaccine Thermostability Platform Opportunity ThermoVax™ Profile Development Plan + World Health Organization reports 50% of all vaccine doses globally are wasted due to excursions from required cold chain temperature ranges + Aluminum-adjuvanted vaccines often require strict adherence to
Slide 16: ThermoVax - Proof of Concept Data
ThermoVax™ - Proof of Concept Data Positive results continue to accrue Physical parameters RiVax™ Incubation 0 days week 1Month 3 month Freeze Dried 100% 100% | 100% 100% 100% 100% | 100% 100% liquid 100% <20% <20% Suspension 40°C 100% <10% | <10% ND Immunogenicity RiVax™ Incubation 0 days week 1mon
Slide 17: Ricin — Evolution Of A Threat
Ricin — Evolution Of A Threat 2011 - al-Qaeda of Yemen threat to use ricin around explosive devices 2010 - al-Qaeda threat to poison food supplies with ricin toxin and cyanide 2008 - Roger Bergendorff in coma after ricin exposure in Las Vegas Motel 2007- Ricin highlighted in FBI terrorism report as
Slide 18: RiVax — Ricin Toxin Vaccine
RiVax™ — Ricin Toxin Vaccine + Category B countermeasures against ricin exposure of rising interest by US government due to recent Terrorist threats and ease of castor bean procurement and production + Interest evidenced by Dept. of Defense's recent RFI for vaccines against ricin exposure entitled,
Slide 19: Anthrax — Evolution Of Threat
Anthrax — Evolution Of Threat 2007 — Confirmed al-Qaeda interest in anthrax development at Tribunal Hearing 2007 — Anthrax highlighted in FBI terrorism report as top bioterror threat along with ricin 2001 - Anthrax attacks via US mail - 5 people dead 1998 — U.S. Secretary of Defense William Cohen ap
Slide 20: VeloThrax — Anthrax Vaccine
VeloThrax™ — Anthrax Vaccine + Category A countermeasures against anthrax exposure clear interest to US/World governments Opportunity * More than $4 billion spent to date on vaccines and therapeutics with recent proposal request by BARDA indicating continued area of unmet medical need + Proprietary
Slide 21: OrbeShield — GI Acute Radiation Syndrome
OrbeSheild™ — GI Acute Radiation Syndrome * Category A countermeasures against radiation exposure of clear interest to UsMorld governments (lyferUGNE —* More than $600 million spent to date on therapeutics against radiation injury with recent funding activity indicating continued area of unmet medic
Slide 22: GI Recovery from Acute Radiation Injury
Gl Recovery from Acute Radiation Injury in Established Beagle Dog Model Survival after 12 Gy TBI (0.7 Gy/min) Treatment Group Median p value vs. Survival control Controls 8 days OrbeShield™ 6 100 days 0.04 (2 HR after TBI) OrbeShield™ 6 87 days 0.048 (24 HR after TBI)
Slide 23: Worldwide Market Potential
Worldwide Market Potential 500 Assumptions 450 Pediatric Crohn’s Disease 400 80,000 Patients US 80,000 Patients EU w 350 ‘Acute Radiation Enteritis c 50,000 Patients US. © 300 50,000 Patients EU = 250 Assumes 2 sublicense deals 200 an Assumes 3 year procurement order of 150 $175 million 100 ‘Assumes
Slide 24: Milestone Events - Past & Future
Milestone Events - Past & Future v* Execution of ThermoVax™ vaccine thermostability license with UC — subject of $9.4 million NIH grant 2011 y+ Completed $30 million EU partnership with Sigma-Tau for orBe + Positive results of OrbeShield™ in preciinical model of GI ARS. Y* Stopped enrollment followi
Slide 25: Thank You
THANK YOU